A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Recruiting · Phase 3 · NCT05519085

Conditions: Relapsed or Refractory Multiple Myeloma

Research payments reported, 2025: $11,163
U.S. investigators named: 7
Sites paid: 7
Planned or actual enrollment: 810

About the trial

Sponsor: Celgene
Tested: mezigdomide (drug), Pomalidomide (drug), Bortezomib (drug), Dexamethasone (drug)
Dates: Started 2022-09-20; completion 2033-11-30
Results posted: Not yet

The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.

From ClinicalTrials.gov, last updated 2026-10-30. Full record, eligibility and contacts (opens in a new tab)

Industry funding

E.r. Squibb & Sons, L.l.c. reported $11,163 in research payments for this study in 2025 (8 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Cancer and Blood Specialty Clinic $3,521
VA Puget Sound Health Care System $2,234
Henry Ford Health Hospital, MI $1,495
New York Cancer & Blood Specialists $1,477
Rochester General Hospital $1,385
Utah Cancer Specialists $716
Fairview Hospital, OH $336

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.

At a glance

About the trial

Industry funding

U.S. investigators named on this study

Sites paid to run it